IL13-PE38QQR
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for IL13-PE38QQR, covering 2011-06-06 to 2011-07-04. Get the full timeline:
Most recent: Clinical Trial Update: IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma [Phase 1]